microRNA 2392 (miR-2392)

microRNA 2392 (miR-2392) is a small non-coding RNA that regulates gene expression post-transcriptionally by binding target mRNAs, leading to translational repression or degradation[3]. It is notably implicated in the host response to SARS-CoV-2 infection, where it drives suppression of mitochondrial gene expression, increases glycolysis, promotes inflammation and hypoxia, and is tightly linked to the metabolic and inflammatory disturbances observed in severe COVID-19 cases[1][2][3]. miR-2392 is detectable in the circulation of COVID-19 patients and serves as a minimally invasive biomarker of infection[1][2]. Beyond viral pathophysiology, miR-2392 also modulates tumor progression, invasion, metastasis, and fibrotic responses, depending on tissue context—frequently acting as a suppressor of invasion in some cancers and a promoter of proliferation in others[1][3]. Therapeutic inhibition of miR-2392 via antisense oligonucleotides is under investigation as an antiviral approach for COVID-19[1]. No approved small-molecule modulators or licensed biomarkers are available, but the unique regulatory role of miR-2392 in mitochondrial gene networks and inflammation makes it a significant emerging target for therapy and diagnostics.

Other names

hsa-miR-2392MIR2392miR-2392hsa-mir-2392

Antisense inhibition of miR-2392 reduces SARS-CoV-2 viability and viral pathophysiology by preventing miR-2392-induced suppression of mitochondrial gene expression and glycolytic upregulation[1].